Our research group has recently examined Her2/neu expression, gene amplification, and its association with outcome in USC, the most aggressive and chemotherapy-resistant variant of endometrial carcinoma (Santin et al, 2002, 2005a, 2005b, 2005c, 2008; El-Sahwi et al, 2010). Here, ERBB2 is linked to endometrial carcinoma.